{
    "organizations": [],
    "uuid": "9077c41a055faff65e1f34b6aa974797cacbc916",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-merck-says-first-time-data-for-key/brief-merck-says-first-time-data-for-keytruda-in-patients-with-previously-treated-advanced-hepatocellular-carcinoma-to-be-presented-at-2018-asco-gi-symposium-idUSFWN1PE0IN",
    "ord_in_thread": 0,
    "title": "Merck says First-Time Data For Keytruda In Patients With Previously Treated Advanced Hepatocellular Carcinoma To Be Presented At 2018 ASCO GI Symposium",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 19 (Reuters) - Merck & Co Inc:\n* FIRST-TIME DATA FOR MERCK‘S KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC) TO BE PRESENTED AT 2018 ASCO GI SYMPOSIUM\n* MERCK & CO INC - SAFETY PROFILE OF KEYTRUDA WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES\n* MERCK & CO INC - SEVEN PATIENTS DISCONTINUED TREATMENT DUE TO TREATMENT-RELATED ADVERSE EVENTS\n* MERCK & CO INC - THERE WAS ONE TREATMENT-RELATED DEATH IN THE STUDY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-19T20:16:00.000+02:00",
    "crawled": "2018-01-19T14:21:01.118+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "merck",
        "co",
        "inc",
        "data",
        "merck",
        "pembrolizumab",
        "patient",
        "previously",
        "treated",
        "advanced",
        "hepatocellular",
        "carcinoma",
        "hcc",
        "presented",
        "asco",
        "gi",
        "symposium",
        "merck",
        "co",
        "inc",
        "safety",
        "profile",
        "keytruda",
        "consistent",
        "observed",
        "previously",
        "reported",
        "study",
        "merck",
        "co",
        "inc",
        "seven",
        "patient",
        "discontinued",
        "treatment",
        "due",
        "adverse",
        "event",
        "merck",
        "co",
        "inc",
        "one",
        "death",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}